tiprankstipranks
Advertisement
Advertisement

KYKOF Stock Latest News

Kyowa Kirin’s New Blood Cancer Trial: What KK2430 Could Mean for KYKOF Investors
Company AnnouncementsKyowa Kirin’s New Blood Cancer Trial: What KK2430 Could Mean for KYKOF Investors
9d ago
KYKOF
Kyowa Kirin Co (KYKOF) Q2 Earnings Cheat Sheet
PremiumPre-Earnings
Kyowa Kirin Co (KYKOF) Q2 Earnings Cheat Sheet
15d ago
Kura, Kyowa Kirin to present updated frontline data from Phase 1 KOMET-007 trial
PremiumThe Fly
Kura, Kyowa Kirin to present updated frontline data from Phase 1 KOMET-007 trial
3M ago
KURA
Kyowa Kirin downgraded to Sell from Buy at Citi
PremiumThe Fly
Kyowa Kirin downgraded to Sell from Buy at Citi
5M ago
Kyowa Kirin downgraded to Underweight from Equal Weight at Morgan Stanley
PremiumThe Fly
Kyowa Kirin downgraded to Underweight from Equal Weight at Morgan Stanley
5M ago
Kyowa Kirin downgraded to Neutral from Outperform at SMBC Nikko
PremiumThe FlyKyowa Kirin downgraded to Neutral from Outperform at SMBC Nikko
5M ago
Kyowa Kirin downgraded to Underweight from Neutral at JPMorgan
Premium
The Fly
Kyowa Kirin downgraded to Underweight from Neutral at JPMorgan
6M ago
Kyowa Kirin announces discontinuation of rocatinlimab clinical trials
Premium
The Fly
Kyowa Kirin announces discontinuation of rocatinlimab clinical trials
6M ago
AMGN
KYKOF Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
KYKOF Upcoming Earnings Report: What to Expect?
6M ago
Kyowa Kirin to regain control of rocatinlimab development, commercialization
PremiumThe Fly
Kyowa Kirin to regain control of rocatinlimab development, commercialization
7M ago
AMGN
Kyowa Kirin downgraded to Sell from Neutral at Goldman Sachs
PremiumThe Fly
Kyowa Kirin downgraded to Sell from Neutral at Goldman Sachs
8M ago
Kyowa Kirin’s Poteligeo Study: A Closer Look at Market Implications
PremiumCompany Announcements
Kyowa Kirin’s Poteligeo Study: A Closer Look at Market Implications
10M ago
KYKOF
Kyowa Kirin’s New Clinical Trial: A Potential Game-Changer in T-Cell Lymphoma Treatment
PremiumCompany AnnouncementsKyowa Kirin’s New Clinical Trial: A Potential Game-Changer in T-Cell Lymphoma Treatment
10M ago
KYKOF
Kyowa Kirin’s Promising Study on KHK4951 for Diabetic Macular Edema
Premium
Company Announcements
Kyowa Kirin’s Promising Study on KHK4951 for Diabetic Macular Edema
10M ago
KYKOF
Kyowa Kirin’s Promising Phase 2 Study on nAMD Treatment: A Market Game-Changer?
Premium
Company Announcements
Kyowa Kirin’s Promising Phase 2 Study on nAMD Treatment: A Market Game-Changer?
10M ago
KYKOF
Kyowa Kirin’s KK8123 Study: A Potential Game-Changer for X-linked Hypophosphatemia
PremiumCompany Announcements
Kyowa Kirin’s KK8123 Study: A Potential Game-Changer for X-linked Hypophosphatemia
10M ago
KYKOF
Kyowa Kirin’s KK3910: A New Hope in Hypertension Treatment?
PremiumCompany Announcements
Kyowa Kirin’s KK3910: A New Hope in Hypertension Treatment?
10M ago
KYKOF
Kyowa Kirin’s Phase 3 Trial on KK8398 for Achondroplasia: A Potential Game-Changer
PremiumCompany Announcements
Kyowa Kirin’s Phase 3 Trial on KK8398 for Achondroplasia: A Potential Game-Changer
10M ago
KYKOF
Kyowa Kirin’s Promising Study on KK2845 for Acute Myeloid Leukemia
PremiumCompany Announcements
Kyowa Kirin’s Promising Study on KK2845 for Acute Myeloid Leukemia
10M ago
KYKOF
Kyowa Kirin’s KK2260 Study: A Potential Game-Changer in Cancer Treatment?
PremiumCompany AnnouncementsKyowa Kirin’s KK2260 Study: A Potential Game-Changer in Cancer Treatment?
10M ago
KYKOF
Kyowa Kirin’s KK2269 Study: A Potential Game-Changer in Solid Tumor Treatment?
Premium
Company Announcements
Kyowa Kirin’s KK2269 Study: A Potential Game-Changer in Solid Tumor Treatment?
10M ago
KYKOF
Kura Oncology receives $30M development milestone payment for ziftomenib
Premium
The Fly
Kura Oncology receives $30M development milestone payment for ziftomenib
10M ago
KURA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >